Lumos Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.

Event:   H.C. Wainwright 24th Annual Global Investment Conference – September 12th-14th
Presentation:   Pre-recorded presentation available beginning September 12th at 7:00 AM (EDT)
Webcast link:   Here
1×1 Meetings:   Management will be available for one-on-one meetings during the conference, September 12th-14th

The webcast for the presentation can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section. Please contact your H.C. Wainwright salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

Staff

Recent Posts

ZLNA – Issuance of shares through set-off of option exercise fee

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's…

10 hours ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon…

10 hours ago

INDY 500 Stars Join Forces with ZERO Prostate Cancer to Put Veterans’ Health in the Spotlight at Memorial Day Weekend Races

INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on…

1 day ago

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI…

1 day ago